CD8A and neoplasm: Paclitaxel, doxorubicin, and cisplatin promote CD8+ T anti-tumor immunity through enhancing induction of cancer cell-autonomous type I interferon via ROS-triggered oxidized mtDNA to activate cGAS-STING in breast cancer (94).